Recently, the National Medical Products Administration（NMPA）The official website shows,Xinhua Pharmaceuticalsubsidiary companyShandong Zibo Xinda Pharmaceutical Co., Ltd.DeclaredClarithromycin for SuspensionApproved for marketing, deemed to have passed the evaluation. According to the Mocent Pharma database,Xinhua PharmaceuticalThe third domestic company approved for this product, and Shandong Xinhua Pharmaceutical Company Limited has obtained it.First company to pass the evaluation！

Screenshot source: NMPA official website

Clarithromycin（clarithromycin）It is a commonly used macrolide antibiotic, primarily indicated for the treatment of infections caused by pathogens sensitive to clarithromycin, including upper respiratory tract infections, lower respiratory tract infections, skin and soft tissue infections, and acute otitis media.

Screenshot source: Moleculeum Global Drug R&D Database

The drug is produced byJapan Taisho Pharmaceutical Co., Ltd.Developed in the 1980s, the original technology was later transferred to Abbott Laboratories and approved by the FDA for marketing in December 1990. It is currently available in over 50 countries and regions worldwide.

1996,Abbott Laboratories（Abbott）Shandong Xinhua Pharmaceutical Company LimitedClarithromycinOriginal drug introduced into the Chinese market and approved for marketing, trade nameKelasian（Klacid）。

In terms of market performance, the drug has achieved a cumulative sales revenue of 13.568 billion yuan in China's hospital market, with annual sales remaining around 1 billion yuan in the past two years, and recorded a year-on-year growth of 6.62% in 2024, indicating a promising market outlook.

Source of the screenshot: Mochou Pharma's National Hospital Sales (All Channels) Database

Currently, in our country,ClarithromycinIncluding various dosage forms such as granules, tablets, dry suspensions, capsules, sustained-release tablets, and injections, among which capsules are the most numerous and one of the mainstream dosage forms.

Source of the screenshot: Mochou Pharma China Drug Approval Database

According to data from Molecent Medical, in the ranking of hospital-based macrolide drug sales,Clarithromycin Sustained-Release Tabletsranked third with 4.663 billion yuan,Clarithromycin TabletsRanked sixth with 2.889 billion yuan, its sustained-release capsule formulation ranked ninth.

Source of the screenshot: Molecent Biopharma National Hospital Sales (All Channels) Database

ThroughoutClarithromycin for Oral SuspensionIts performance in the Chinese domestic market is particularly outstanding. Starting a period of rapid growth in 2021, it achieved annual growth rates of 66.24%, 26.25%, 39.81%, and 65.03% from 2021 to 2024 respectively, with sales exceeding 85 million yuan in 2024, demonstrating considerable market potential.

Source of the screenshot: Mochou Pharma's National Hospital Sales (All Channels) Database

Xinhua PharmaceuticalThis approval followsSino-American Huadong Pharmaceutical Co., Ltd.、Apel Pharmaceuticalthe third domestic company approvedClarithromycin for Suspensionenterprise, and the first company to pass the evaluation for this formulation. It not only helps establish a competitive landscape of one original drug plus three domestic versions, but also enhances the company's market competitiveness.

Screenshot source: Mochou Pharma Consistency Evaluation Database

RecentlyXinhua PharmaceuticalIssued three announcements in a row, announcing the successful acquisitionMinoxidil Solution、Clarithromycin for Oral Suspension、Sacubitril Valsartan Sodium TabletsThree major products were launched, and the company announced its 2025 interim report, with operating revenue reaching 4.64 billion yuan and net profit attributable to shareholders amounting to 224 million yuan.

Screenshot source: Mochou Pharma China Drug Approval Database

It is worth noting that since the beginning of this yearXinhua Pharmaceuticaland its subsidiaries have cumulatively obtainedEmpagliflozin Tablets、Dapagliflozin Tablets、Tadalafil Tablets、Pregabalin Oral Solutionand 22 production approvals for 18 new products, covering 11 subcategories, including painkillers, cardiovascular medicines, urological drugs, and other fields. As new products are approved one after another, the company's product portfolio will develop towards a more comprehensive and diversified direction.

END

This article is original; please leave a message to obtain authorization for reprinting.